SageView Advisory Group LLC Purchases Shares of 12,175 Haleon plc (NYSE:HLN)

SageView Advisory Group LLC purchased a new stake in shares of Haleon plc (NYSE:HLN) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 12,175 shares of the company’s stock, valued at approximately $100,000.

Other hedge funds have also modified their holdings of the company. Hexagon Capital Partners LLC lifted its position in shares of Haleon by 107.3% during the fourth quarter. Hexagon Capital Partners LLC now owns 4,236 shares of the company’s stock valued at $35,000 after buying an additional 2,193 shares during the last quarter. Pinnacle Bancorp Inc. increased its holdings in shares of Haleon by 853.4% during the fourth quarter. Pinnacle Bancorp Inc. now owns 4,767 shares of the company’s stock valued at $39,000 after acquiring an additional 4,267 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Haleon by 146.8% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,398 shares of the company’s stock valued at $44,000 after acquiring an additional 3,211 shares in the last quarter. SRS Capital Advisors Inc. increased its holdings in shares of Haleon by 456.4% during the fourth quarter. SRS Capital Advisors Inc. now owns 5,458 shares of the company’s stock valued at $45,000 after acquiring an additional 4,477 shares in the last quarter. Finally, Hoxton Planning & Management LLC acquired a new position in shares of Haleon during the fourth quarter valued at about $85,000. 6.67% of the stock is owned by hedge funds and other institutional investors.

Haleon Price Performance

Shares of NYSE:HLN opened at $8.58 on Friday. Haleon plc has a twelve month low of $7.70 and a twelve month high of $8.96. The company’s 50 day moving average is $8.38 and its 200 day moving average is $8.33. The company has a current ratio of 1.04, a quick ratio of 0.73 and a debt-to-equity ratio of 0.53. The company has a market cap of $39.18 billion, a PE ratio of 28.60, a price-to-earnings-growth ratio of 2.25 and a beta of 0.26.

Haleon (NYSE:HLN) last issued its quarterly earnings results on Wednesday, May 1st. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.01. Haleon had a net margin of 9.68% and a return on equity of 13.17%. The company had revenue of $3.70 billion for the quarter, compared to the consensus estimate of $3.71 billion. On average, sell-side analysts forecast that Haleon plc will post 0.46 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Berenberg Bank assumed coverage on shares of Haleon in a report on Wednesday, June 5th. They set a “buy” rating on the stock. HSBC assumed coverage on shares of Haleon in a report on Wednesday, April 17th. They set a “buy” rating on the stock. Finally, Argus restated a “buy” rating on shares of Haleon in a report on Tuesday, March 26th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy”.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.